Indivior PLC Files 8-K Current Report

TL;DR

Indivior filed a routine 8-K on Oct 1st, no new info.

AI Summary

Indivior PLC filed an 8-K on October 1, 2025, to report current information. The filing primarily serves as a notification of events and does not contain specific financial results or material business updates beyond its procedural nature. The company, incorporated in England and Wales, is listed under the Pharmaceutical Preparations SIC code.

Why It Matters

This filing indicates that Indivior PLC is adhering to its regulatory obligations by submitting a current report. It does not provide new financial information or strategic updates that would immediately impact investors.

Risk Assessment

Risk Level: low — This is a standard procedural filing with no new material information, financial data, or strategic changes that would inherently increase risk.

Key Numbers

• 001-37835 — SEC File Number (Identifies the company's filing history with the SEC.)
• 98-1204773 — IRS Employer Identification No. (Tax identification number for the company.)

Key Players & Entities

• INDIVIOR PLC (company) — Registrant
• October 1, 2025 (date) — Date of earliest event reported
• England and Wales (jurisdiction) — State or other jurisdiction of incorporation
• 2834 (sic_code) — Standard Industrial Classification

FAQ

Key Financial Figures

• $0.50 — on which registered Ordinary shares, $0.50 nominal value per share INDV The Nasdaq

Filing Documents

• indv-20251001.htm (8-K) — 28KB
• ex99110012025intenttoredom.htm (EX-99.1) — 19KB
• 0001628280-25-043293.txt ( ) — 165KB
• indv-20251001.xsd (EX-101.SCH) — 2KB
• indv-20251001_lab.xml (EX-101.LAB) — 21KB
• indv-20251001_pre.xml (EX-101.PRE) — 12KB
• indv-20251001_htm.xml (XML) — 3KB

01 Regulation FD Disclosure

Item 7.01 Regulation FD Disclosure. On October 1, 2025, Indivior PLC ("Indivior" or the "Company") issued a press release announcing its intent to redomicile in Delaware. The press release is furnished as Exhibit 99.1 to this report and is incorporated herein. This Item 7.01 contains forward-looking statements with respect to the Company's intent to redomicile in Delaware, the potential timing and prospects for such action, and the potential benefits. Such statements involve many risks and uncertainties that could cause actual results to differ materially from those expressed or implied, including those associated with: the need for court approval in the U.K., the need for shareholder approval, changes in the timing and execution of the Company's cost and capital reduction initiatives; actions of third parties beyond the Company's control, and other risks and uncertainties described in the Company's Annual Report on Form 10-K filed March 3, 2025, Quarterly Report on Form 10-Q filed May 1, 2025, Quarterly Report on Form 10-Q filed July 31, 2025, Quarterly Report on Form 10-Q filed October 30, 2025, and other filings with the SEC. All information herein reflects management's expectations as of the date hereof, unless an earlier date is specified. The Company does not undertake, and expressly disclaims, any duty to update such statements, whether as a result of new information, new developments, or otherwise, except to the extent that doing so may be required by law.

01 Exhibits

Item 9.01 Exhibits (d) Exhibits. Exhibit No. Description 99.1 Press release issued by Indivior PLC dated October 1, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Indivior PLC Date: October 1, 2025 By: /s/ Ryan Preblick Name: Ryan Preblick Title: Chief Financial Officer

View Full Filing

View this 8-K filing on SEC EDGAR